VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CATXPerspective Therapeutics, Inc.
$3.03$234M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCATXRevenue History

CATX logoPerspective Therapeutics, Inc. (CATX) Revenue History

Annual and quarterly revenue from 1994 to present

TTM Revenue$575K
YoY Growth—
Q1 2026$76K
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$10.8M (2021)
Best Quarter$2.9M (Q1 2022)
Revenue per Share$0.01
Revenue per Employee$4K

CATX Revenue Over Time (1994–2025)

CATX Revenue Growth History

12 of 24 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
1994—
1995+15.2%
1996+5.6%
1997-5.0%
1998-100.0%
1999—
2000—
2001—
2002—
2003—
2004—
2005+888.6%
2006+187.7%
2007+24.8%
2008-24.3%
2009-2.4%
2010-0.9%
2011-3.2%
2012-10.8%
2013-6.8%
2014+9.2%
2015+3.5%
2016-0.2%
2017+24.4%
2018+23.5%
2019+32.3%
2020+3.9%
2021+7.4%
2022-34.2%
2023-79.8%
2024-100.0%
2025—
FY1994 revenue growth
N/A
FY1995 revenue growth
+15.2%
FY1996 revenue growth
+5.6%
FY1997 revenue growth
-5.0%
FY1998 revenue growth
-100.0%
FY1999 revenue growth
N/A
FY2000 revenue growth
N/A
FY2001 revenue growth
N/A
FY2002 revenue growth
N/A
FY2003 revenue growth
N/A
FY2004 revenue growth
N/A
FY2005 revenue growth
+888.6%
FY2006 revenue growth
+187.7%
FY2007 revenue growth
+24.8%
FY2008 revenue growth
-24.3%
FY2009 revenue growth
-2.4%
FY2010 revenue growth
-0.9%
FY2011 revenue growth
-3.2%
FY2012 revenue growth
-10.8%
FY2013 revenue growth
-6.8%
FY2014 revenue growth
+9.2%
FY2015 revenue growth
+3.5%
FY2016 revenue growth
-0.2%
FY2017 revenue growth
+24.4%
FY2018 revenue growth
+23.5%
FY2019 revenue growth
+32.3%
FY2020 revenue growth
+3.9%
FY2021 revenue growth
+7.4%
FY2022 revenue growth
-34.2%
FY2023 revenue growth
-79.8%
FY2024 revenue growth
-100.0%
FY2025 revenue growth
N/A
DeclineStrong growth
Best: +888.6% (FY2005)Worst: -100.0% (FY1998)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$76K—
Q4 2025$0—
Q3 2025$209K—
Q2 2025$290K—
Q1 2025$0—
Q4 2024$0-100.0%
Q3 2024$0-100.0%
Q2 2024$0-100.0%
Seasonal Revenue Pattern (fiscal quarters)
Q1
23%
Q2
26%
Q3
25%
Q4
27%

Multi-year avg. share of annual revenue by fiscal quarter

CATX Revenue Analysis (1994–2025)

Current Revenue & Growth

As of June 28, 2026, Perspective Therapeutics, Inc. (CATX) generated trailing twelve-month (TTM) revenue of $575,000. The most recent quarter (Q1 2026) recorded $76,000 in revenue

Historical Growth Trajectory

CATX's historical revenue data shows various trends over time. Perspective Therapeutics, Inc.'s highest annual revenue of $10.8 million was recorded in 2021.

Peer Comparison

Compared to Healthcare sector peers — including AGEN (+24.5% YoY), RNW (+36.9% YoY), and LNTH (+0.6% YoY). Compare CATX vs AGEN →

CATX Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
CATX logoCATXCurrent$575,000---
AGEN logoAGEN$114M+24.5%+5.3%-18.0%
RNW logoRNW$139.1B+36.9%+23.6%43.4%
LNTH logoLNTH$1.5B+0.6%+35.3%20.2%
NVX logoNVX$6M-13.6%+1.5%-929.6%
Best in groupLowest in group

CATX Historical Revenue Data (1994–2025)

1–15 of 32 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-113,564,000-
2024$0-100.0%$0-$10.5M-
2023$1.4M-79.8%$1.4M100.0%$-40,941,000-2855.0%
2022$7.1M-34.2%$1.6M23.0%$-15,182,000-213.7%
2021$10.8M+7.4%$4.6M42.8%$-7,391,000-68.5%
2020$10.1M+3.9%$5.1M50.9%$-3,437,000-34.2%
2019$9.7M+32.3%$5.1M52.9%$-3,476,000-35.9%
2018$7.3M+23.5%$3.0M41.7%$-5,278,000-72.2%
2017$5.9M+24.4%$1.8M31.1%$-6,729,000-113.6%
2016$4.8M-0.2%$838K17.6%$-6,307,000-132.5%
2015$4.8M+3.5%$129K2.7%$-5,082,003-106.6%
2014$4.6M+9.2%$167K3.6%$-4,336,187-94.1%
2013$4.2M-6.8%$-196,471-4.7%$-4,588,218-108.7%
2012$4.5M-10.8%$150K3.3%$-4,067,253-89.9%
2011$5.1M-3.2%$703K13.9%$-3,597,970-71.0%
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

32+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CATX — Frequently Asked Questions

Quick answers to the most common questions about buying CATX stock.

Is CATX's revenue growth accelerating or slowing?

CATX TTM revenue: $575000.00. YoY growth: N/A. 5-year CAGR: N/A.

What is CATX's revenue history from 1994 to 2026?

Perspective Therapeutics, Inc. (CATX) revenue history spans 1994 to 2026. TTM revenue as of 2026 is $575000.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is CATX's long-term revenue growth rate (CAGR)?

Perspective Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CATX.

Why does CATX's quarterly revenue fluctuate?

CATX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Perspective Therapeutics, Inc.'s revenue data from 1994 to 2026 shows full historical quarterly detail on this page.

How is CATX's revenue distributed by segment?

CATX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does CATX's revenue compare to industry peers?

Perspective Therapeutics, Inc. (CATX) with TTM revenue of $575000.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.